CD304 is preferentially expressed on a subset of B-lineage acute lymphoblastic leukemia and represents a novel marker for minimal residual disease detection by flow cytometry

Cytometry Part A

Volumn 81 A, Issue 1, 2012, Pages 17-24

  Solly, Françoise ^a,b   Angelot, Fanny ^a,c   Garand, Richard ^d   Ferrand, Christophe ^a,c   Seillès, Estelle ^a,c   Schillinger, Françoise ^a   Decobecq, Agnès ^a   Billot, Maryse ^a   Larosa, Fabrice ^e   Plouvier, Emmanuel ^e   Deconinck, Eric ^c,e   Legrand, Faezeh ^e   Saas, Philippe ^a,c   Rohrlich, Pierre Simon ^c,e   Garnache Ottou, Francine ^a,c  

^a ETABLISSEMENT FRANÇAIS DU SANG   (France)

^b UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^c UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^d NANTES UNIVERSITY HOSPITAL   (France)

^e UNIVERSITY HOSPITAL OF BESANÇON   (France)

Author keywords

B lineage acute lymphoblastic leukemia; CD304; Flow cytometry; Minimal residual disease; NRP 1

Indexed keywords

BIOLOGICAL MARKER; NEUROPILIN 1; ONCOPROTEIN; TEL AML1 FUSION PROTEIN; TEL-AML1 FUSION PROTEIN; TRANSCRIPTION FACTOR RUNX1;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; B LYMPHOCYTE; CELL LINEAGE; FEMALE; FLOW CYTOMETRY; GENE REARRANGEMENT; GENETICS; HUMAN; IMMUNOLOGY; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; MINIMAL RESIDUAL DISEASE;

ADOLESCENT; ADULT; B-LYMPHOCYTES; BIOLOGICAL MARKERS; CELL LINEAGE; CORE BINDING FACTOR ALPHA 2 SUBUNIT; FEMALE; FLOW CYTOMETRY; GENE REARRANGEMENT; HUMANS; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; NEUROPILIN-1; ONCOGENE PROTEINS, FUSION; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; YOUNG ADULT;

EID: 83855162770     PISSN: 15524922     EISSN: 15524930     Source Type: Journal    
DOI: 10.1002/cyto.a.21162     Document Type: Article

References (25)

1. Bielenberg DR, Pettaway CA, Takashima S, Klagsbrun M. Neuropilins in neoplasms: Expression, regulation, and function. Exp Cell Res 2006; 312: 584-593.
2. Garnache-Ottou F, Feuillard J, Ferrand C, Biichle S, Trimoreau F, Seilles E, Salaun V, Garand R, Lepelley P, Maynadie M, et al. Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia. Br J Haematol 2009; 145: 624-636.
3. Vales A, Kondo R, Aichberger KJ, Mayerhofer M, Kainz B, Sperr WR, Sillaber C, Jager U, Valent P. Myeloid leukemias express a broad spectrum of VEGF receptors including neuropilin-1 (NRP-1) and NRP-2. Leuk Lymphoma 2007; 48: 1997-2007.
4. Kreuter M, Woelke K, Bieker R, Schliemann C, Steins M, Buechner T, Berdel WE, Mesters RM. Correlation of neuropilin-1 overexpression to survival in acute myeloid leukemia. Leukemia 2006; 20: 1950-1954.
5. Kreuter M, Steins M, Woelke K, Buechner T, Berdel WE, Mesters RM. Downregulation of neuropilin-1 in patients with acute myeloid leukemia treated with thalidomide. Eur J Haematol 2007; 79: 392-397.
6. Karjalainen K, Jaalouk DE, Bueso-Ramos CE, Zurita AJ, Kuniyasu A, Eckhardt BL, Marini FC, Lichtiger B, O'Brien S, Kantarjian HM, et al. Targeting neuropilin-1 in human leukemia and lymphoma. Blood 2011; 117: 920-927.
7. Coustan-Smith E, Song G, Clark C, Key L, Liu P, Mehrpooya M, Stow P, Su X, Shurtleff S, Pui CH, et al. New markers for minimal residual disease detection in acute lymphoblastic leukemia. Blood 2011; 117: 6267-6276.
8. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006; 354: 166-178.
9. Cave H, van der Werff ten Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J, Bakkus M, Thielemans K, Grandchamp B, Vilmer E. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer-Childhood Leukemia Cooperative Group. N Engl J Med 1998; 339: 591-598.
10. Beldjord K, Lhéritier V, Boulland ML, Grardel N, Cayuela JM, Cavé H, Schäfer B, Bakkus M, Garrido M, Dhédin N, et al. Post-induction minimal residual disease (MRD) defines a large subset of adults with favorable PH-negative acute lymphoblastic leukemia (ALL), who do not benefit from allogeneic stem cell transplantation (SCT) in first complete remission: A GRAALL Study. Blood (ASH Annual Meeting Abstracts) 2009; 114:Abstract 577.
11. De Moerloose B, Suciu S, Bertrand Y, Mazingue F, Robert A, Uyttebroeck A, Yakouben K, Ferster A, Margueritte G, Lutz P, et al. Improved outcome with pulses of vincristine and corticosteroids in continuation therapy of children with average risk acute lymphoblastic leukemia (ALL) and lymphoblastic non-Hodgkin lymphoma (NHL): Report of the EORTC randomized phase 3 trial 58951. Blood 2010; 116: 36-44.
12. Huguet F, Leguay T, Raffoux E, Thomas X, Beldjord K, Delabesse E, Chevallier P, Buzyn A, Delannoy A, Chalandon Y, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: The GRAALL-2003 study. J Clin Oncol 2009; 27: 911-918.
13. Kerst G, Kreyenberg H, Roth C, Well C, Dietz K, Coustan-Smith E, Campana D, Koscielniak E, Niemeyer C, Schlegel PG, et al. Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR. Br J Haematol 2005; 128: 774-782.
14. Chen W, Karandikar NJ, McKenna RW, Kroft SH. Stability of leukemia-associated immunophenotypes in precursor B-lymphoblastic leukemia/lymphoma: A single institution experience. Am J Clin Pathol 2007; 127: 39-46.
15. Campana D, Coustan-Smith E. Detection of minimal residual disease in acute leukemia by flow cytometry. Cytometry 1999; 38: 139-152.
16. Robillard N, Cavé H, Méchinaud F, Guidal C, Garnache-Ottou F, Rohrlich P, Avet-Loiseau H, Garand R. Four-colour flow cytometry bypasses limitations of polymerase chain reaction for minimal residual disease detection in certain subsets of children with acute lymphoblastic leukemia. Haematologica 2005; 90: 1516-1523.
17. Campana D, Coustan-Smith E, Janossy G. The immunologic detection of minimal residual disease in acute leukemia. Blood 1990; 76: 163-171.
18. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N, Barbany G, Cazzaniga G, Cayuela JM, Cave H, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-A Europe Against Cancer program. Leukemia 2003; 17: 2318-2357.
19. Stow P, Key L, Chen X, Pan Q, Neale GA, Coustan-Smith E, Mullighan CG, Zhou Y, Pui CH, Campana D. Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia. Blood 2010; 115: 4657-4663.
20. Ciudad J, Orfao A, Vidriales B, Macedo A, Martinez A, Gonzalez M, Lopez-Berges MC, Valverde B, San Miguel JF. Immunophenotypic analysis of CD19+ precursors in normal human adult bone marrow: Implications for minimal residual disease detection. Haematologica 1998; 83: 1069-1075.
21. Bene MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Orfao A, van't Veer MB. Proposals for the immunological classification of acute leukemias. European group for the immunological characterization of leukemias (EGIL). Leukemia 1995; 9: 1783-1786.
22. Zelent A, Greaves M, Enver T. Role of the TEL-AML1 fusion gene in the molecular pathogenesis of childhood acute lymphoblastic leukaemia. Oncogene 2004; 23: 4275-4283.
23. Pan Q, Chen X, Behm F, Raimondi SC, Pui CH, A. NG. Neuropilins, ectopically expressed in relapsed childhood acute lymphoblastic leukemia, enhance lymphoid survival and promote tumorigenesis. In: Abstracts of the 42nd Annual Meeting of the American Society of Hematology; San Francisco, CA. 2000.
24. Gandemer V, Aubry M, Roussel M, Rio AG, de Tayrac M, Vallee A, Mosser J, Ly-Sunnaram B, Galibert MD. CD9 expression can be used to predict childhood TEL/AML1-positive acute lymphoblastic leukemia: Proposal for an accelerated diagnostic flowchart. Leuk Res 2010; 34: 430-437.
25. Ross ME, Mahfouz R, Onciu M, Liu HC, Zhou X, Song G, Shurtleff SA, Pounds S, Cheng C, Ma J, et al. Gene expression profiling of pediatric acute myelogenous leukemia. Blood 2004; 104: 3679-3687.